Abliva AB (publ)

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. Show More...

  • Website https://abliva.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.04 EUR
  • Last Updated 17-03-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share SEK -0.23 -0.45 -0.65 -0.9 -1.24 -2.44 -1.35 -1.2 -0.87 -0.45 -0.43
    Dividends SEK
    Payout Ratio % *
    Shares Mil 21.0 21.0 23.0 25.0 34.0 38.0 52.0 56.0 78.0 172.0 186.0
    Book Value Per Share * EUR 0.38 0.42 0.29 0.17 0.11 0.08 0.04
    Free Cash Flow Per Share * EUR -0.2 -0.22 -0.17 -0.11 -0.08 -0.03
    Return on Assets % -17.86 -24.71 -28.24 -27.8 -38.6 -58.86 -39.5 -44.36 -58.09 -58.37 -49.12
    Financial Leverage (Average) 1.02 1.05 1.12 1.18 1.27 1.24 1.16 1.19 1.19 1.16 1.08
    Return on Equity % -18.59 -25.58 -30.89 -32.0 -47.6 -73.74 -47.37 -52.1 -69.16 -68.5 -52.71
    Return on Invested Capital % -16.83 -26.78 -30.89 -32.0 -46.99 -74.28 -47.33 -51.99 -68.55 -68.5 -52.71
    Interest Coverage -6.89 -81.12 -207.74 -944.33 -482.8 -121.08
    Current Ratio 29.3 8.26 4.51 2.86 2.19 4.94 7.74 2.28 1.56 2.95 3.84
    Quick Ratio 28.58 8.01 4.48 2.82 2.17 4.92 7.74 2.28 1.56 2.92 3.76
    Debt/Equity